Characteristics | Drug report, n (%) | |
---|---|---|
TCZ | SAR | |
Patient age (year) | Â | Â |
18–44 | 20 (10.42%) | 0 (0.00%) |
45–64 | 58 (30.21%) | 3 (3.61%) |
65–74 | 21 (10.94%) | 0 (0.00%) |
75–84 | 11 (5.73%) | 0 (0.00%) |
 ≥ 85 | 2 (1.04%) | 0 (0.00%) |
Unknown | 80 (41.67%) | 80 (96.39%) |
Patient gender | Â | Â |
Female | 25 (13.02%) | 1 (1.20%) |
Male | 89 (46.35%) | 2 (2.41%) |
Unknown | 78 (40.63%) | 80 (96.39%) |
Reporter occupation | Â | Â |
Consumer | 2 (1.04%) | 0 (0.00%) |
Pharmacist | 52 (27.08%) | 1 (1.20%) |
Physician | 64 (33.33%) | 82 (98.80%) |
Unknown | 74 (38.54%) | 0 (0.00%) |
Report time | Â | Â |
2020Q2 | 13 (6.77%) | 6 (7.23%) |
2020Q3 | 29 (15.10%) | 13 (15.66%) |
2020Q4 | 23 (11.98%) | 61 (73.49%) |
2021Q1 | 20 (10.42%) | 3 (3.61%) |
2021Q2 | 53 (27.60%) | 0 (0.00%) |
2021Q3 | 25 (13.02%) | 0 (0.00%) |
2021Q4 | 29 (15.10%) | 0 (0.00%) |
Area | Â | Â |
Africa | 2 (1.04%) | 0 (0.00%) |
Asian | 22 (11.46%) | 0 (0.00%) |
Europe | 102 (53.13%) | 13 (15.66%) |
North America | 53 (27.60%) | 63 (75.90%) |
South America | 13 (6.77%) | 7 (8.43%) |
Outcomes | Â | Â |
Congenital anomaly | 0 (0.00%) | 1 (1.22%) |
Death | 30 (17.14%) | 30 (36.59%) |
Disability | 1 (0.57%) | 1 (1.22%) |
Hospitalization initial or prolonged | 27 (15.43%) | 37 (45.12%) |
Life-threatening | 6 (3.42%) | 29 (35.37%) |
Other serious (important medical event) | 137 (78.29%) | 54 (65.85%) |
Required intervention to prevent permanent impairment | 2 (1.14%) | 0 (0.00%) |